» Articles » PMID: 19089993

A Novel Role of ERK5 in Integrin-mediated Cell Adhesion and Motility in Cancer Cells Via Fak Signaling

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2008 Dec 18
PMID 19089993
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

In metastatic cancer, high expression levels of vitronectin (VN) receptors (integrins), FAK, and ERK5 are reported. We hypothesized that integrin-mediated ERK5 activation via FAK may play a pivotal role in cell adhesion, motility, and metastasis. ERK5 and FAK phosphorylation when metastatic MDA-MB-231 and PC-3 cells were plated on VN was enhanced. Further experiments showed co-immunoprecipitation of integrins beta1, alpha V beta 3, or alpha V beta 5 with ERK5 and FAK. To gain better insight into the mechanism of ERK5, FAK, and VN receptors in cell adhesion and motility, we performed loss-of-function experiments using integrin blocking antibodies, and specific mutants of FAK and ERK5. Ectopic expression of dominant negative ERK5/AEF decreased ERK5 and FAK (Y397) phosphorylation, cell adhesion, and haptotactic motility (micromotion) on VN. Additionally, DN FAK expression attenuated ERK5 phosphorylation, cell adhesion, and motility. This study documents the novel finding that in breast and prostate cancer cells, ERK5 is a critical target of FAK in cell adhesion signaling. Using different cancer cells, our experiments unveil a novel mechanism by which VN receptors and FAK could promote cancer metastasis via ERK5 activation.

Citing Articles

Bone and Extracellular Signal-Related Kinase 5 (ERK5).

Wen L, Liu Z, Zhou L, Liu Z, Li Q, Geng B Biomolecules. 2024; 14(5).

PMID: 38785963 PMC: 11117709. DOI: 10.3390/biom14050556.


Quantitative glycoproteomics analysis identifies novel FUT8 targets and signaling networks critical for breast cancer cell invasiveness.

Tu C, Li F, Li L, Yang R Breast Cancer Res. 2022; 24(1):21.

PMID: 35303925 PMC: 8932202. DOI: 10.1186/s13058-022-01513-3.


Clinical Significance and Regulation of ERK5 Expression and Function in Cancer.

Monti M, Celli J, Missale F, Cersosimo F, Russo M, Belloni E Cancers (Basel). 2022; 14(2).

PMID: 35053510 PMC: 8773716. DOI: 10.3390/cancers14020348.


The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.

Xu Q, Zhang J, Telfer B, Zhang H, Ali N, Chen F Oncogene. 2021; 40(23):3929-3941.

PMID: 33981002 PMC: 8195737. DOI: 10.1038/s41388-021-01798-2.


Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.

Bhatt A, Patel S, Matossian M, Ucar D, Miele L, Burow M Biomolecules. 2021; 11(2).

PMID: 33572742 PMC: 7911413. DOI: 10.3390/biom11020183.


References
1.
Sawhney R, Cookson M, Sharma B, Hauser J, Brattain M . Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells. J Biol Chem. 2004; 279(45):47379-90. DOI: 10.1074/jbc.M402031200. View

2.
McNeel D, Eickhoff J, Lee F, King D, Alberti D, Thomas J . Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res. 2005; 11(21):7851-60. DOI: 10.1158/1078-0432.CCR-05-0262. View

3.
Shimaoka M, Springer T . Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov. 2003; 2(9):703-16. DOI: 10.1038/nrd1174. View

4.
Lin H, Lansing L, Merillon J, Davis F, Tang H, Shih A . Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J. 2006; 20(10):1742-4. DOI: 10.1096/fj.06-5743fje. View

5.
Giaever I, Keese C . Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci U S A. 1991; 88(17):7896-900. PMC: 52411. DOI: 10.1073/pnas.88.17.7896. View